CHENGDU, China, May 8, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or the “Company”) announced that the sNDA (the “Application”) for the Company’s TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱^®) was accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China. The application is for sac-TMT in combination with MSD’s^[1] anti-PD-1 monoclonal antibody pembrolizumab (KEYTRUDA^®[2]) as first‑line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have PD-L1 tumor proportion score (TPS) ≥1% and are EGFR-negative and ALK-negative. This acceptance is based on the positive results from the OptiTROP-Lung05 registrational Phase III study, and the application is the fifth indication application for sac-TMT that has been accepted by the NMPA.

The OptiTROP-Lung05 is a randomized, open-label, multicenter, Phase III clinical study that evaluates the efficacy and safety profile of sac-TMT in combination with pembrolizumab versus pembrolizumab monotherapy as first-line treatment for PD-L1-positive locally advanced or metastatic NSCLC. At a pre-specified interim analysis, the study has met its primary endpoint of progression-free survival (PFS) and demonstrated a statistically significant and clinically meaningful improvement as concluded by the Independent Data Monitoring Committee (IDMC). A positive trend in overall survival (OS) was also observed. Notably, the OptiTROP-Lung05 study is the first Phase III study of an immunotherapy and ADC combination to meet its primary endpoint in first-line NSCLC treatment. The study has been selected for an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract number #8506, Lung Cancer –Non-Small Cell Metastatic).

Previously, sac-TMT in combination with intravenous and subcutaneous pembrolizumab for the first-line treatment of patients with locally advanced or metastatic NSCLC who have PD-L1 TPS≥1% and are EGFR-negative and ALK-negative was granted Breakthrough Therapy Designation (BTD) by the NMPA. On April 9, 2026, the CDE’s official website announced that the Application has entered the priority review and approval process. This marks the fifth sac-TMT indication to enter the CDE’s priority review and approval process. Through this process, the review time will be significantly shortened, potentially expediting its approval pathways.

Dr. Michael Ge, CEO of Kelun-Biotech said, “We are delighted to see the acceptance of the fifth indication application for sac-TMT. Compared to immunotherapy alone, the ADC combination with KEYTRUDA^® as first-line treatment for PD-L1-positive NSCLC has achieved not only positive results in PFS, but also a trend toward benefit in OS. This achievement holds significant importance for improving current treatment regimens for lung cancer. We will continue to collaborate with our partners to advance the clinical development and commercialization of sac-TMT, to help more patients with lung cancer and enhance their survival outcomes.”

About sac-TMT

Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, breast cancer (BC), gastric cancer (GC), gynecological tumors and genitourinary tumors, among others. Sac-TMT is developed with a unique, bifunctional linker that maximizes payload delivery to tumor cells both through its irreversible connection with the anti-TROP2 monoclonal antibody sacituzumab and its pH-sensitive cleavage from a belotecan-derivative topoisomerase I inhibitor payload in the lysosome, with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases the payload KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells.

In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc, Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (which includes Mainland China, Hong Kong, Macao and Taiwan).

To date, four indications for sac-TMT have been approved and marketed in China for: 1) unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting); 2) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy; 3) EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC who progressed after treatment with EGFR-TKI therapy; 4) unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+ or IHC 2+/ISH-) BC who have received prior ET and at least one line of chemotherapy in advanced setting. The first two indications above have been included in China’s National Reimbursement Drug List (NRDL). This inclusion is expected to bring clinically meaningful benefits to a greater number of patients with BC and NSCLC. Additionally, sac-TMT has been granted six Breakthrough Therapy Designations (BTDs) by the NMPA.

Sac-TMT is the world’s first TROP2 ADC drug approved for marketing in lung cancer. A new indication application for sac-TMT in combination with pembrolizumab (KEYTRUDA^®) as first‑line treatment for locally advanced or metastatic NSCLC who have PD-L1 TPS≥1% and are EGFR-negative and ALK-negative has been accepted for review by the NMPA, and has entered the priority review and approval process. As of today, Kelun-Biotech has initiated 9 registrational clinical studies in China. MSD has initiated 17 ongoing global Phase III clinical studies of sac-TMT as a monotherapy or in combination with pembrolizumab or other anti-cancer agents for several types of cancer. These studies are sponsored and led by MSD.

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world’s leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/. 

Source

BEIJING, May 8, 2026 /PRNewswire/ — Sohu.com Limited (NASDAQ: SOHU), a leading Chinese online media platform and game business group, will report its first quarter 2026 unaudited financial results on Monday, May 18, 2026, before U.S. market hours.

Sohu’s management team will host a conference call on the same day at 5:00 a.m. U.S. Eastern Time, May 18, 2026 (5:00 p.m. Beijing/Hong Kong time, May 18, 2026) following the quarterly results announcement.

Conference Call Preregistration

Participants can register for the conference call by clicking here, you will be led to the conference registration website. Upon registration, each participant will receive details for the conference call, including dial-in numbers and a unique access PIN. Please dial in 10 minutes before the call is scheduled to begin.

The live webcast and archive of the conference call will be available on the Investor Relations section of Sohu’s website at https://investors.sohu.com/.

About Sohu

Sohu.com Limited (NASDAQ: SOHU) was established by Dr. Charles Zhang, one of China’s internet pioneers, in the 1990s. Sohu operates one of the leading Chinese online media platforms and also engages in the online game business in the Chinese mainland. Sohu has built one of the most comprehensive matrices of Chinese language web properties, consisting of Sohu News App, Sohu Video App, the mobile portal m.sohu.com, the PC portal www.sohu.com, and the online games platform www.changyou.com/en/.

As a mainstream media platform with social features, Sohu is indispensable to the daily life of millions of Chinese, providing to a vast number of users a network of web properties and community based products, which offer a broad array of content, such as news and information, in the form of text, picture, video, and live broadcasting. Sohu also attracts users to actively engage in content generation and distribution, and actively interact with each other on the platform. Sohu’s online game business is conducted by its subsidiary Changyou, which develops and operates a diverse portfolio of PC and mobile games, such as the well-known Tian Long Ba Bu (“TLBB”) PC and Legacy TLBB Mobile.

For investor and media inquiries, please contact:

Sohu.com Limited
Ms. Pu Huang
Tel:        +86 (10) 6272-6645
E-mail:   ir@contact.sohu.com

Christensen Advisory 
E-mail:  sohu@christensencomms.com

Source

ABU DHABI, UAE, May 7, 2026 /PRNewswire/ — Speaking at Milken Institute Global Conference, one of the most influential cross-sector forums convening leaders in policy, investment and innovation, H.E. Mansoor Ibrahim Al Mansoori, Chairman of the Department of Health – Abu Dhabi (DOH), invited global partners, investors and innovators to, “build, test and scale next-generation health solutions in Abu Dhabi.”

H.E.Mansoor Al Mansoori- Reimagining Healthcare, for Abu Dhabi and Beyond Session

Al Mansoori positioned Abu Dhabi as a global test-bed for AI-enabled for real-world health innovation, underpinned by a fully integrated, intelligent health infrastructure, “AI, for us, is not hype, it is a utility. We are accelerating drug discovery by integrating comprehensive data like genotype, phenotype, and information from wearables into an AI-enabled system. This intelligent platform acts as a real-world evidence engine, allowing companies to assess product impact in real-time…Abu Dhabi is a ‘living lab’, and the invitation is open.”

Al Mansoori continued, “Every health system needs to have foresight, it is a responsibility. In Abu Dhabi, our intelligence-based system integrates all types of health data into one single platform that gives full visibility…so you can have the pulse of your system at any time.”

He highlighted the role of AI Agents within the emirate’s Unified Medical Operations Command Centre (UMOC) in creating foresight and resilience, “the UMOC is the ‘health brain’ of our system. Today, [with AI Agents] we have forty times the manpower of our workforce, detecting incidents in real-time, enabling faster emergency response, care that starts in the ambulance and creating a continuous intelligence loop.”

Al Mansoori continued, “Over the past period, our system didn’t pause. We kept going, delivering and accelerating. Abu Dhabi’s long-term plan in health, and in general, is grounded in economic diversification, strategic investment in technology and infrastructure, investing in people, empowered by deep capital reserve.”

On the sidelines of the conference, Al Mansoori also met with a select group of leaders in longevity, AI, biotechnology, paediatrics, genomics and investment during a dinner hosted under the Future Health – A Global Initiative by Abu Dhabi platform. The discussion focused on advancing practical models for anticipatory health systems, expanding equitable access to predictive care, and exploring new financing models that prioritise long-term health outcomes.

To watch the full conversation, please click here.

Source

Huawei’s Bangkok Launch Ignites All-Scenario Intelligence, Opening a New Chapter of Smart Life

BANGKOK, May 7, 2026 /PRNewswire/ — On May 7, 2026, Huawei held the “Now Is Your Spark” global product launch in Bangkok, Thailand, where they officially unveiled the HUAWEI MatePad Pro Max, HUAWEI WATCH FIT 5 Series, HUAWEI WATCH GT Runner 2 Racing Legend Edition, and other innovative products. With all-scenario technology, these devices serve as a genuine extension for global users to explore the world and express themselves.

An ultra-slim flagship tablet setting new benchmarks in mobile productivity

Huawei globally debuted the HUAWEI MatePad Pro Max at this launch. Combining refined design, a premium display, PC-level productivity, and a full suite of creative tools, the HUAWEI MatePad Pro Max provides flagship tablet performance in a remarkably thin and light form factor. At 499g and measuring a mere 4.7 mm thick, even the exclusive PaperMatte Edition weighs just 509g, HUAWEI MatePad Pro Max is the thinnest and lightest tablet among the 13-inch+ tablet.

Smart wearables refreshed for the next generation

Huawei has introduced a fresh lineup of smart wearables tailored for the young generation. The HUAWEI WATCH FIT 5 Series retains its iconic square design, now enhanced with a sleek, vibrant aesthetic. It guides users through engaging and accessible mini-workouts, encouraging a more active lifestyle. The series also supports a wide range of competitive sports, including cycling, golf, trail running, and tennis. With advanced tracking, analysis, and guidance features, it caters to diverse needs, from daily fitness routines to competitive sport.

Debuting at this event, the HUAWEI WATCH GT Runner 2 Racing Legend Edition is a professional running watch that embodies the look and feel of marathon racing. It features a new single running ability index (RAI) and a professional Training Camp Dashboard, giving runners deeper data insights to train smarter and race harder.

Huawei partnered with renowned jewelry designer Francesca Amfitheatrof to launch the HUAWEI WATCH ULTIMATE DESIGN Spring Edition. Inspired by the blooming beauty of spring, this design features 99 natural diamonds and diamond-cut sapphire glass, a wearable celebration of feminine strength and vitality.

Huawei has also unveiled new premium flagship kids watches: the HUAWEI WATCH KIDS X1 Series. Equipped with a front and rear high-definition camera setup, it features a 110° ultra-wide-angle front camera and a 1.82-inch AMOLED screen, offering a larger display and broader field of view. The device also includes a detachable and rotatable device body and AR fun feature, enabling kids to capture every precious moment of their explorations.

A new phone experience for the diverse needs of young users

Huawei officially launched the HUAWEI nova 15 Max, redefining the experience for a generation that plays hard and shoots sharp. Equipped with a 50 MP RYYB Ultra Vision Camera, it delivers true-to-life colors even in low light or backlit conditions. The 8,500 mAh Super Battery powers all-day use, eliminating battery anxiety. The Extra-Durable Body is drop-resistant, so everyday bumps are no longer a worry. Combined with a Vivid OLED Screen and Symmetrical Stereo Dual Speakers, an immersive audio-visual experience is always within reach. From photography to battery life, and from durability to audio-visuals, the HUAWEI nova 15 Max continuously empowers every passion.

From flagship tablets to smartwatches designed for children, Huawei’s connected device ecosystem continues to expand its presence in the daily lives of users around the world. Huawei remains committed to technology that is not only useful, but genuinely enriching, technology that ignites inspiration. Huawei looks forward to continued collaboration with users around the world, helping people live and work better, wherever they are.

Source

SEOUL, South Korea and SHANGHAI, May 7, 2026 /PRNewswire/ — Taimei Technology (HK.02576), a leading AI-powered drug clinical development platform company, and C&R Research (A359090), a top-tier CRO in South Korea, signed an enterprise-level strategic partnership agreement, officially launching the development of an AI-based clinical trial operations system.

Under this partnership, C&R Research will deploy Taimei Technology’s leading digital infrastructure and AI Agents across multiple clinical trials to automate and enhance trial design and operational workflows. A particular focus will be on data management, where the EDC + iDM Agent combination will be actively adopted. Innovations such as intelligent data capture and governance, AI-driven eCRF generation, and automated test case creation are expected to boost productivity and quality in clinical research.

Leveraging its full-stack AI capabilities, 13 years of industry expertise, and global operational experience, Taimei Technology has deeply focused on the clinical research vertical, and has been among the first to build a comprehensive AI Agent matrix, enabling scenario-based AI applications across the entire clinical research workflow. Key offerings include eCollect (EDC), eBalance (RTSM), eCOA, eCooperate (CTMS), and eArchives (eTMF), iDM Agent, iCTA Agent, iPV Agent; as well as the iMAP intelligent medical analytics platform etc. These products can be flexibly configured to address critical pain points across clinical research—from efficiency to scientific insights—significantly improving trial efficiency and success rates.

The two companies plan to integrate AI-driven operational models with Korea’s CRO-centric clinical trial execution system, thereby building a more efficient and intelligent clinical research framework.

Korea has established a mature ecosystem in innovative drug development and clinical execution, with clinical trial activity and participation in global pipelines ranking among the top worldwide. Industry observers believe this partnership goes beyond technology adoption and will serve as a key catalyst for accelerating the AI-driven digital transformation of South Korea’s clinical trial landscape.

Moon Tae Yoon, CEO of C&R Research, commented: “As clinical trials become increasingly complex, AI-based data management and operational automation are emerging as essential competitive factors. Through this partnership, we will build a more efficient and innovative clinical execution system.”

Zhao Lu, Chairman of Taimei Technology, stated: “This partnership represents an important opportunity to bring the AI clinical operations experience we have accumulated in global markets into South Korea. We look forward to collaborating with more Korean ecosystem partners to continuously drive the intelligent transformation of clinical trials.”

Source

PARIS, May 7, 2026 /PRNewswire/ — In autumn 2026, in the wake of the Venice Biennale, the Lyon Biennale of Contemporary Art establishes itself as one of the major events on the international artistic calendar.

18th Lyon Biennale Contemporary Art – 2026

As France’s leading contemporary art event, each edition brings together nearly 300,000 visitors and generates more than 2.7 million encounters with artworks in public space, affirming a unique model in which artistic production, dissemination, territorial engagement and international reach converge on a large scale.

More than an exhibition, the Lyon Biennale now constitutes an international platform of influence, situated at the intersection of artistic scenes, institutions, collectors, foundations, professionals and global economic dynamics.

18th Lyon Biennale of Contemporary Art
Passer d’un rêve à l’autre / To pass from one dream to another
Lyon, France | September 19 – December 13, 2026
https://www.labiennaledelyon.com/en

Download Press Kit: https://www.labiennaledelyon.com/en/espace-presse-art

After Venice, Lyon: a new centre of gravity for the global art scene

The 18th Lyon Biennale of Contemporary Art will take place at the heart of autumn 2026, at a strategic moment within the international contemporary art calendar. It extends, shifts and reactivates the major artistic conversations initiated in Venice, grounding them within a singular territory: Lyon, a city of passages, exchanges and transformations.

Within this urban, historical and economic geography, the Biennale transforms Lyon into a full-scale space for experimentation, where artworks engage in dialogue with heritage, industrial, museum and public sites.

Catherine Nichols: an international curatorial voice on the rise

The 18th edition is entrusted to Catherine Nichols, a Berlin-based curator, writer and art historian. She was recently appointed Artistic Director of Manifesta, within the framework of a new co-directorship model that will come into effect from October 2026 onward.

With Passer d’un rêve à l’autre, Catherine Nichols develops an ambitious project centred on the notion of “poetic economy,” inspired by Robert Filliou. Here, the economy is not approached merely as a financial system: it becomes a sensitive infrastructure composed of relationships, flows, narratives, visible and invisible labour, and material as well as immaterial values.

Rooted in Lyon’s history — a city shaped by commerce, circulation, silk production, industry and confluences — this reflection takes on both a local and profoundly global dimension.

An expanded artistic cartography: new scenes, new narratives

Bringing together more than 70 international artists, this edition is distinguished by a strong openness toward artistic scenes still insufficiently represented in Europe, particularly from Australia and New Zealand, and spanning more than thirty nationalities. These territories engage in dialogue with the French and European scenes within a framework that brings together major figures, established artists and emerging voices.

The Biennale thus constructs an expanded artistic cartography in which questions of value, care, heritage, production and transformation run across practices, generations and geographies.

Artists – (full list to be completed in June)

Akwasi Bediako Afrane, Lara Almarcegui, Joël Andrianomearisoa, Serwah Attafuah, Béatrice Balcou, Eva Barto, Lucy Beech, Rossella Biscotti, Barbara Breitenfellner, Yuriyal Eric Bridgeman, Sara Sejin Chang (Sara van der Heide), Fiona Clark, Lua Coderch, Léa Collet, June Crespo, cyan, Edith Dekyndt, Huong Dodinh, Yana Nafysa Dombrowsky-M’baye, Mikala Dwyer, Robert Filliou, Florian Fouché, Rose Frigière, Angela Goh, Birke Gorm, Nuria Güell, Alice Guy, Oda Haliti, Archana Hande, Matthew Harris, Timo Hogan, Ngahina Hohaia, Jelena Jureša, Lucia Kagramanyan, Kirtika Kain, Mikhail Karikis, Ndayé Kouagou, Perrine Lacroix, Maureen Lander, Ida Lawrence, James Lewis, LYL Radio, Kokou Ferdinand Makouvia, Nicholas Mangan, Angelica Mesiti, Hana Miletić, Hayley Millar Baker, Jazz Money, Mai Nguyen-Long, Manfred Paul, Thea Anamara Perkins, Susan Philipsz, Laure Prouvost, raumlaborberlin, Miguel Rothschild, Selma Selman, Erwan Séné, Igor Šimić, Sriwhana Spong, Tina Stefanou, Mette Sterre, Michael Stevenson, Pol Taburet, Huda Takriti, Tsuneko Taniuchi, Ashleigh Taupaki, Minh Lan Tran, Thu-Van Tran, Álvaro Urbano, Kaylene Whiskey, Luke Willis Thompson, Candrani Yulis.

Exhibition venues

• macLYON – Museum of Contemporary Art
• Les Grandes Locos
• Museum of Textiles and Decorative Arts
• Traboules of the Croix-Rousse slopes – free access
• Garden of the Museum of Fine Arts – free access
• IAC – Institute of Contemporary Art / Frac Rhône-Alpes
• Musée des Confluences
• Bullukian Foundation – free access
• LPA Saint-Antoine car park – free access
• Metro line B station – Gare Part-Dieu

An international platform for production and influence

The Lyon Biennale is simultaneously a site for the production of new works, an international professional hub and a space for reflection on contemporary transformations. It is embedded within a global network, notably through the International Biennial Association, and each edition welcomes artists, curators, institutions, foundations, partners and art market actors.

Through its artistic projects, professional programmes, international collaborations, mediation initiatives and participatory projects, the Lyon Biennale asserts a singular model: a leading event open to the widest possible audience and fully engaged with the issues of its time.

Key dates

• September 16–18, 2026: Press Days
• September 17–18, 2026: Professional Days
• September 18, 2026: Preview / Opening
• September 19, 2026: Public Opening
• December 13, 2026: Closing Date

About the Lyon Biennale

For more than forty years, the Lyon Biennale has organised two major events on the cultural scene in France and internationally: the Biennale of Contemporary Art and the Dance Biennale.

As the institution responsible for the conception, programming and implementation of these two events, the Lyon Biennale is today recognised as one of the major international events dedicated to contemporary creation. It enjoys strong recognition among professionals, the press and audiences alike.

Its commitment is based on four core missions: an ethical mission, through the development of a sensitive relationship to the world via visual arts and dance; a social mission, through openness to all audiences and the creation of social bonds; an economic mission, through its contribution to the visibility and attractiveness of the territory; and a CSR mission, through a socially responsible approach toward all its stakeholders.

Creativity, excellence, rigour, solidarity, social diversity and inclusivity lie at the heart of the Lyon Biennale project.

Governance

• President: Laurent Bayle
• Chief Executive Officer: Cécile Bourgeat
• Artistic Director of the Lyon Biennale of Contemporary Art: Isabelle Bertolotti
• Curator: Catherine Nichols

The 2026 Lyon Biennale embodies a unique model and has established itself as a must-attend event on the international scene. Twenty-six years after their first collaboration, Artprice by Artmarket and La Demeure du Chaos are partnering with the 18th Lyon Biennale.

A must-attend event on the international Art calendar, the Lyon Biennale has established itself, following in Venice’s footsteps, as much more than an exhibition: a platform of influence where artists, institutions, collectors, foundations, and key players in the global Art Market converge.

Twenty-six years after “Partage d’Exotisme”- the legendary 2000 Biennial curated by Jean-Hubert Martin, which served as a follow-up to his famous 1989 exhibition “Les Magiciens de la Terre” at the Centre Georges Pompidou and caused a sensation in the West. This Biennial brought together Artprice by Artmarket and La Demeure du Chaos as patrons for the first time. In 2026, they will once again join the Lyon Contemporary Art Biennial as committed partners for its 18th edition.

Thierry Ehrmann, founder of Artprice, president of Artmarket, and visual artist for over four decades, creator of La Demeure du Chaos – officially recognized on March 20, 2025 as a “Total Work of Art” by Minister of Culture Rachida Dati, applauds the significance of this Biennale of Contemporary Art, which engages with the geographical and economic characteristics of the city of Lyon.

It is in this spirit that the two entities are joining forces to support the work of Selma Selman, an artist who employs performance, painting, photography, and video to embody the struggles of her community, questioning the value of labor, objects, and bodies. She extracts the hidden poetry from industrial materials – and reminds us that beauty, too, is born of Chaos.

https://www.artprice.com/artprice-news

Contact: econometrics@artprice.com

Catherine Nichols, Isabelle Bertolotti – Photo: Blandine Soulage

Source